UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 27

Sortiert nach

MAIT cell activation augments adenovirus vector vaccine immunogenicity

Science (American Association for the Advancement of Science), 2021-01, Vol.371 (6528), p.521-526

2021

Volltextzugriff (PDF)

Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade

Nature communications, 2019-06, Vol.10 (1), p.2688-12, Article 2688

2019

Volltextzugriff (PDF)

Multimerization and Retention of the Scavenger Receptor SR-B1 in the Plasma Membrane

Developmental cell, 2019-08, Vol.50 (3), p.283-295.e5

2019

Volltextzugriff (PDF)

In vitro adaptation and characterization of attenuated hypervariable region 1 swap chimeras of hepatitis C virus

PLoS pathogens, 2021-07, Vol.17 (7), p.e1009720-e1009720

2021

Volltextzugriff (PDF)

Human anti-nucleolin recombinant immunoagent for cancer therapy

Proceedings of the National Academy of Sciences - PNAS, 2015-07, Vol.112 (30), p.9418-9423

2015

Volltextzugriff (PDF)

Adenovirus Encoded Adjuvant (AdEnA) anti-CTLA-4, a novel strategy to improve Adenovirus based vaccines against infectious diseases and cancer

Frontiers in immunology, 2023-04, Vol.14, p.1156714-1156714

2023

Volltextzugriff (PDF)

Optineurin Increases Cell Survival and Translocates to the Nucleus in a Rab8-dependent Manner upon an Apoptotic Stimulus

The Journal of biological chemistry, 2006-06, Vol.281 (23), p.16147-16156

2006

Volltextzugriff (PDF)

Vector Aided Microenvironment programming (VAMP): reprogramming the TME with MVA virus expressing IL-12 for effective antitumor activity

Journal for immunotherapy of cancer, 2023-04, Vol.11 (4), p.e006718

2023

Volltextzugriff (PDF)

Development of a Potency Assay for Nous-209, a Multivalent Neoantigens-Based Genetic Cancer Vaccine

Vaccines (Basel), 2024-03, Vol.12 (3), p.325

2024

Volltextzugriff (PDF)

VENUS, a Novel Selection Approach to Improve the Accuracy of Neoantigens’ Prediction

Vaccines (Basel), 2021-08, Vol.9 (8), p.880

2021

Volltextzugriff (PDF)

Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion

Journal for immunotherapy of cancer, 2021-11, Vol.9 (11), p.e003480

2021

Volltextzugriff (PDF)

Differential binding of human immunoagents and Herceptin to the ErbB2 receptor

The FEBS journal, 2008-10, Vol.275 (20), p.4967-4979

2008

Volltextzugriff (PDF)

A Genetic Vaccine Encoding Shared Cancer Neoantigens to Treat Tumors with Microsatellite Instability

Cancer research (Chicago, Ill.), 2020-09, Vol.80 (18), p.3972-3982

2020

Volltextzugriff (PDF)

Targeted invalidation of SR-B1 in macrophages reduces macrophage apoptosis and accelerates atherosclerosis

Cardiovascular research, 2020-03, Vol.116 (3), p.554-565

2020

Volltextzugriff (PDF)

Targeted invalidation of SR-B1 in macrophages reduces macrophage apoptosis and accelerates atherosclerosis

Cardiovascular research, 2020-03, Vol.116 (3), p.554-565

2020

Volltextzugriff (PDF)

Adenovirus vectors activate Vδ2+ γδT cells in a type I interferon‐, TNF‐, and IL‐18‐dependent manner

European journal of immunology, 2022-05, Vol.52 (5), p.835-837

2022

Volltextzugriff (PDF)

Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine

Cancer immunology research, 2024-04, Vol.12 (4), p.440

2024

Volltextzugriff (PDF)

Lipophilicity is a Key Factor to Increase the Antiviral Activity of HIV Neutralizing Antibodies

Biophysical journal, 2016-02, Vol.110 (3), p.572a-573a

2016

Volltextzugriff (PDF)

Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice

Gut, 2016-12, Vol.65 (12), p.2029-2034

2016

Volltextzugriff (PDF)

Lipophilicity is a key factor to increase the antiviral activity of HIV neutralizing antibodies

Colloids and surfaces, B, Biointerfaces, 2017-04, Vol.152, p.311-316

2017

Volltextzugriff (PDF)

Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries

BioMed research international, 2019, Vol.2019, p.6051870-22

2019

Volltextzugriff (PDF)

Longitudinal transcriptomic and genetic landscape of radiotherapy response in canine melanoma

Veterinary & comparative oncology, 2019-09, Vol.17 (3), p.308-316

2019

Volltextzugriff (PDF)

Dramatic Potentiation of the Antiviral Activity of HIV Antibodies by Cholesterol Conjugation

The Journal of biological chemistry, 2014-12, Vol.289 (50), p.35015-35028

2014

Volltextzugriff (PDF)

novel ErbB2 epitope targeted by human antitumor immunoagents

The FEBS journal, 2011-04, Vol.278 (7), p.1156-1166

2011

Volltextzugriff (PDF)

Abstract B105: A cancer vaccine targeting many neoantigens is required for effective eradication of large tumors

Cancer immunology research, 2019-02, Vol.7 (2_Supplement), p.B105-B105

2019

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(27)

Sprache

Englisch
(27)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

MAIT cell activation augments adenovirus vector vaccine immunogenicity

Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade

Multimerization and Retention of the Scavenger Receptor SR-B1 in the Plasma Membrane

In vitro adaptation and characterization of attenuated hypervariable region 1 swap chimeras of hepatitis C virus

Human anti-nucleolin recombinant immunoagent for cancer therapy

Adenovirus Encoded Adjuvant (AdEnA) anti-CTLA-4, a novel strategy to improve Adenovirus based vaccines against infectious diseases and cancer

Optineurin Increases Cell Survival and Translocates to the Nucleus in a Rab8-dependent Manner upon an Apoptotic Stimulus

Vector Aided Microenvironment programming (VAMP): reprogramming the TME with MVA virus expressing IL-12 for effective antitumor activity

Development of a Potency Assay for Nous-209, a Multivalent Neoantigens-Based Genetic Cancer Vaccine

VENUS, a Novel Selection Approach to Improve the Accuracy of Neoantigens’ Prediction

Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion

Differential binding of human immunoagents and Herceptin to the ErbB2 receptor

A Genetic Vaccine Encoding Shared Cancer Neoantigens to Treat Tumors with Microsatellite Instability

Targeted invalidation of SR-B1 in macrophages reduces macrophage apoptosis and accelerates atherosclerosis

Targeted invalidation of SR-B1 in macrophages reduces macrophage apoptosis and accelerates atherosclerosis

Adenovirus vectors activate Vδ2+ γδT cells in a type I interferon‐, TNF‐, and IL‐18‐dependent manner

Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine

Lipophilicity is a Key Factor to Increase the Antiviral Activity of HIV Neutralizing Antibodies

Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice

Lipophilicity is a key factor to increase the antiviral activity of HIV neutralizing antibodies

Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries

Longitudinal transcriptomic and genetic landscape of radiotherapy response in canine melanoma

Dramatic Potentiation of the Antiviral Activity of HIV Antibodies by Cholesterol Conjugation

novel ErbB2 epitope targeted by human antitumor immunoagents

Abstract B105: A cancer vaccine targeting many neoantigens is required for effective eradication of large tumors

Suchergebnisse filtern